Intravenous Nalbuphine for Prevention of Intrathecal Morphine-induced Nausea and Vomiting in Pati… (NCT06837129) | Clinical Trial Compass
CompletedNot Applicable
Intravenous Nalbuphine for Prevention of Intrathecal Morphine-induced Nausea and Vomiting in Patients Undergoing Cesarean Section: A Double-blind, Randomized Controlled Trial.
Thailand180 participantsStarted 2023-11-15
Plain-language summary
We study efficacy of iv nalbuphine in prevention of intrathecal morphine-induced nausea and vomiting in patients undergoing cesarean section.
Who can participate
Age range18 Years – 45 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Elective cesarean section under spinal anesthesia
* age \> 18 years
Exclusion Criteria:
* Patients with known allergy to medications used in this study (nalbuphine, bupivacaine or morphine)
* Patient with medical conditions which spinal anesthesia is contraindicated ie. heart diseases, renal or hepatic impairment, obesity \>=100 kilograms
* Patients with history of postoperative nausea and vomiting (PONV) or motion sickness who may have preexisting risk factors for PONV
* Patient with known history of drug abuse
* Unwilling to participate in the study
What they're measuring
1
Incidence of postoperative nausea vomiting in 24 hours